Nursing care
GLP-1 Agonists: what to check before you give it
Written and reviewed by Dana Whitfield, RN, MSN · 5 min read · Updated September 2026
Short answer
GLP-1 agonists lower blood glucose by slowing gastric emptying, stimulating glucose-dependent insulin release, and suppressing glucagon. That same delayed emptying causes the nausea most patients report and the aspiration risk anaesthetists ask about before surgery. Screen for personal or family history of medullary thyroid carcinoma or MEN 2 before the first dose.
Why this drug and not another
GLP-1 receptor agonists are prescribed over sulfonylureas when a patient needs glucose control without the hypoglycaemia risk that comes with insulin secretagogues acting independently of blood glucose. Because GLP-1 drugs stimulate insulin release only when glucose is elevated, hypoglycaemia on monotherapy is uncommon. That profile makes them a common second-line choice after metformin, especially where weight loss or cardiovascular risk reduction is also a treatment goal.
The same mechanism that controls glucose also slows the stomach. Delayed gastric emptying reduces the post-meal glucose spike, but it is the reason this class carries a side-effect profile different from oral hypoglycaemics. A nurse choosing to flag a GLP-1 order for review, or explaining to a patient why this drug was selected over glipizide, is really explaining gastric emptying and glucose-dependent insulin release in one sentence.
Administration and timing
Most GLP-1 agonists are given by subcutaneous injection, with dosing frequency varying by drug: some are daily, others weekly. Oral semaglutide exists but requires strict administration rules — taken first thing in the morning, on an empty stomach, with no more than 4 oz of plain water, and no food, drink, or other oral medication for at least 30 minutes afterward. Missing that window means the dose is essentially lost, since absorption depends on an empty, undiluted stomach.
For injectable forms, rotate sites between the abdomen, thigh, and upper arm, and do not mix the injection into the same syringe as insulin unless a combination product specifies otherwise. Titration schedules matter clinically: doses usually start low and increase at set intervals, precisely because starting at the maintenance dose maximises the nausea and delayed emptying that already come with this class. Confirm the patient is on the correct step of the titration before administering, not just the correct drug.
Monitoring parameters
Track fasting glucose and HbA1c as the primary efficacy markers, alongside weight, which drops in most patients and is often part of the reason the drug was prescribed. Renal function is worth monitoring too: significant vomiting or diarrhoea from delayed gastric emptying can cause dehydration and acute kidney injury, particularly in patients who already have reduced renal reserve.
Pancreatic symptoms need a lower threshold for investigation on this class than on most diabetes medications. Persistent, severe abdominal pain radiating to the back, with or without vomiting, should prompt lipase and amylase checks and a hold on the next dose pending review. Gallbladder disease is also more common with rapid weight loss on GLP-1 therapy, so right-upper-quadrant pain deserves the same attention.
Adverse effects to report
Nausea, vomiting, and diarrhoea are expected early in treatment and during dose escalation, and usually settle over one to two weeks at a stable dose. What separates expected from reportable is severity and duration: vomiting that prevents oral intake, diarrhoea lasting more than a few days, or any sign of dehydration such as reduced urine output or postural dizziness should go back to the prescriber rather than being managed as routine.
Report suspected pancreatitis immediately, and treat any new, persistent hoarseness, dysphagia, neck swelling, or a palpable neck mass as a possible thyroid finding requiring urgent evaluation rather than reassurance. Injection-site reactions are usually minor, but a patient reporting rapid heart rate alongside anxiety or sweating warrants a glucose check to rule out concurrent hypoglycaemia from another agent in their regimen.
Contraindications and cautions
GLP-1 agonists carry a boxed warning for thyroid C-cell tumours based on rodent studies, and they are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. This is the single contraindication most exam questions and most medication reconciliation checks are built around, and it is a history question, not a lab value, so it has to be asked directly rather than inferred from current thyroid function tests.
Use with caution in patients with a history of pancreatitis, severe gastrointestinal disease, or gastroparesis, since delayed gastric emptying compounds an already slow-moving gut. These drugs are not recommended for type 1 diabetes or diabetic ketoacidosis, and caution is warranted in pregnancy, where most agents in this class are not recommended and should be discontinued before a planned pregnancy.
Teaching points the exam tests
Expect NCLEX-style questions to pair the mechanism with the symptom: delayed gastric emptying explains both the therapeutic effect and the nausea, and questions often ask which finding is expected versus which requires the nurse to notify the provider. A patient reporting mild nausea in week one is expected; a patient reporting persistent vomiting and epigastric pain radiating to the back is not.
The other recurring test point is the thyroid history question. Expect a scenario where a patient with a family history of medullary thyroid cancer is prescribed a GLP-1 agonist, and the correct nursing action is to hold the medication and clarify with the prescriber before administering, not to give it and monitor. Teaching should cover injection technique, the importance of completing dose titration as scheduled, recognising signs of dehydration, and reporting neck changes or severe abdominal pain without delay.
The next step on this is the same as on everything else here: answer questions and read the rationales. Our endocrine practice questions are the closest set to what this page covers.
Common questions
Can GLP-1 agonists cause hypoglycaemia on their own?
Rarely, because insulin release is glucose-dependent. The risk rises sharply when a GLP-1 agonist is combined with insulin or a sulfonylurea, so check the full medication list before assuming hypoglycaemia is unlikely.
Why is oral semaglutide taken on an empty stomach with only a small amount of water?
Absorption depends on the drug reaching the stomach lining undiluted and before food or other medications interfere. Taking it with more water, food, or other oral drugs within 30 minutes significantly reduces how much of the dose is absorbed.
Is nausea a reason to stop a GLP-1 agonist?
Mild to moderate nausea during dose titration is expected and usually improves within one to two weeks. Stop and notify the prescriber only if it is severe, persistent, or accompanied by vomiting that prevents oral intake, signs of dehydration, or abdominal pain suggesting pancreatitis.
Do GLP-1 agonists need to be held before surgery?
Many anaesthesia guidelines recommend holding injectable GLP-1 agonists for a period before elective procedures under sedation or general anaesthesia because delayed gastric emptying raises aspiration risk. Follow the specific facility protocol and confirm timing with the anaesthesia team, since recommendations vary by drug and by institution.
What thyroid symptoms should a patient on a GLP-1 agonist report?
Any new, persistent hoarseness, difficulty swallowing, neck swelling, or a lump felt in the neck should be reported promptly. These are not expected side effects and warrant evaluation given the class's boxed warning for thyroid C-cell tumours.